We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cytarabine-induced corneal toxicity.
- Authors
Lochhead, J; Salmon, J F; Bron, A J
- Abstract
Cytarabine (cytosine arabinoside) is a powerful antimetabolite used in the treatment of acute myeloid leukaemia (AML). Routine prophylaxis with topical steroids is now an established part of the treatment protocol. The cytotoxic activity of cytarabine is related to the concentration and duration of exposure, both of which vary with different modes of administration. There are no reports of corneal toxicity in patients receiving an intermittent, intravenous low-dose regimen, and currently no recommendations have been made for prophylaxis in these cases. A 39-year-old male presented with a 1-day history of blurred vision, severe discomfort and photophobia following a 10-day course of intermittent low-dose intravenous cytarabine therapy for AML. The mechanism of cytarabine-induced microcyst formation is not currently known.
- Subjects
STEROID drugs; ANTIMETABOLITES; ACUTE myeloid leukemia treatment; CORNEA diseases; PEOPLE with visual disabilities
- Publication
Eye, 2003, Vol 17, Issue 5, p677
- ISSN
0950-222X
- Publication type
Article
- DOI
10.1038/sj.eye.6700451